Ethereum Is Soaring. 3 Reasons Investors Should Pay Attention.
Ethereum is now up 65% over the past 30 days, and is starting to decouple from Bitcoin.
Ethereum's recent performance could signal the arrival of "altcoin season," when risky, speculative cryptocurrencies tend to outperform.
New crypto legislation is opening up high-growth opportunities for Ethereum in areas such as stablecoins.
10 stocks we like better than Ethereum ›
Seemingly out of nowhere, Ethereum (CRYPTO: ETH) has become one of the hottest cryptocurrencies on the planet. It's now up 65% over the past 30 days, and analysts are busy ratcheting up their price targets for just how high Ethereum might go in 2025 and beyond.
Ethereum's rapid rise over the past few months could have important implications for your investment portfolio. Here are three reasons why investors should be paying attention.
The arrival of "altcoin season"?
Ethereum's rise has been so meteoric that it is now outpacing Bitcoin (CRYPTO: BTC), which is only up 15% over the past 30 days. This isn't supposed to happen. Historically, there has been a very tight correlation between price movements in Bitcoin and Ethereum.
As a result, some investors are already starting to suggest that Ethereum's decoupling from Bitcoin could signal the arrival of "altcoin season." This is the time of the year when investors shift away from Bitcoin and into riskier, more speculative cryptocurrencies (such as viral meme coins) in search of higher returns.
Typically, the first tell-tale sign of "altcoin season" is when Ethereum starts to overheat. This is then followed by money flowing into riskier and riskier cryptocurrencies, until a vast speculative bubble starts to form. If history is any guide, this is what could be happening now.
Already, investors are starting to talk up the types of cryptos that might "pop" during this altcoin season. So, any vacation you might have planned during August could be the perfect time to think about ways you can diversify your portfolio away from Bitcoin in order to capture some of this potential upside.
New momentum for Ethereum in two key areas
Two new pieces of crypto legislation -- the Genius Act and the Clarity Act -- are now passing through Congress, and hopes are already building about what this could mean for Ethereum. The thinking here is that the combination of the Genius Act (which governs stablecoins) and the Clarity Act (which provides a regulatory framework for all digital assets) might create a sort of "perfect storm" for Ethereum's future development.
That's because Ethereum is a powerhouse when it comes to both stablecoins and decentralized finance (DeFi), and these are exactly the two areas of the crypto market that this new legislation is designed to help.
With that in mind, investors need to keep their eyes open for new investment opportunities that involve DeFi, and especially those that involve stablecoins. The hype around stablecoins might be a bit overblown, but even the most cynical investor has to admit that something huge is happening here. Stablecoins have grown from a sleepy $20 billion industry in 2020 to a $250 billion industry today. And Treasury Secretary Scott Bessent thinks stablecoins could hit $2 trillion within just a few years.
A new way to invest in Ethereum
Finally, keep your eyes open for new ways to invest in Ethereum. Arguably, the most exciting of these opportunities are the new Ethereum Treasury Companies that have been appearing ever since the end of May. There are now three publicly traded companies -- Bitmine Immersion Technologies (NYSEMKT: BMNR), Bit Digital (NASDAQ: BTBT), and SharpLink Gaming (NASDAQ: SBET) -- that have ditched their old business models and gone all-in on Ethereum. And one more -- The Ether Machine -- is on its way.
The goal of these companies is to become "the Strategy (NASDAQ: MSTR) of Ethereum." Strategy has become one of the top-performing publicly traded companies in the world by building up a massive Bitcoin position on its balance sheet. In a similar way, companies are now racing to amass Ethereum on their balance sheets, in the hopes of delivering similar types of performance.
For investors, this opens up new possibilities. It might be the case, for example, that you can earn higher returns by investing in these Ethereum Treasury Companies than by investing in Ethereum itself.
Before you invest in Ethereum
Does all this sound too good to be true? Maybe it is. After all, even though Ethereum has turned in some blistering performance of late, it's still only up 10% for the year. If you look at a chart for Ethereum for 2025, you'll see that it's been a roller coaster ride. Ethereum was on a rapid downward path for the first five months of the year, and is now rising nearly as fast on the upside.
As a result, some of the updated price forecasts for Ethereum might be overly optimistic. The all-time high for Ethereum is under $5,000, but some are already predicting that Ethereum could hit $15,000 soon. That just doesn't seem to be realistic. So before you invest in Ethereum, make sure you do your due diligence.
Should you invest $1,000 in Ethereum right now?
Before you buy stock in Ethereum, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ethereum wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!*
Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 21, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
Pagaya Closes Upsized $500 Million 8.875% Senior Unsecured Notes Offering, Signaling Strong Investor Confidence
Pagaya Technologies Ltd. (NASDAQ: PGY) ('Pagaya' or the 'Company'), a global technology company delivering AI-driven product solutions for the financial ecosystem, today announced the successful closing of its upsized offering of $500 million of 8.875% senior unsecured notes due 2030 (the 'notes'). Net proceeds from the offering will be used primarily to refinance the existing higher-cost term loan and other secured borrowings. The transaction marks a significant milestone in Pagaya's evolution as a public company, establishing it as one of the first fintechs to access the high-yield unsecured debt markets. Backed by strong demand from many of the world's leading institutional investors, the deal was upsized and approximately 5 times oversubscribed. 'Executing a $500 million high-yield offering with significant investor demand is a milestone that reflects the strength of our financial profile and the institutional support of our platform,' said Gal Krubiner, Co-Founder and CEO of Pagaya. 'This achievement strengthens our ability to scale, drive sustained profitability, and deliver long-term shareholder value.' By refinancing legacy debt and eliminating associated debt amortization, Pagaya further improves its GAAP Net Income profitability and expects to generate approximately $40 million of annualized cash flow savings, based on first quarter 2025 performance, resulting from the following: ~$30 million in reduced debt amortization (a portion of the annualized first quarter 2025 payments made to secured borrowings and long-term debt) and approximately $12 million in annual interest expense reduction. The transaction is expected to lower Pagaya's cost of debt by nearly 200 basis points, while maintaining generally flat net leverage. This offering builds on Pagaya's capital strategy, establishing repeatable access to public debt markets, enhancing capital flexibility, and broadening its long-term investor base. The Company is now rated by all three major credit agencies: S&P, Moody's, and Fitch. 'This transaction is the result of our disciplined financial strategy designed to strengthen our financial foundation, accelerate profitability, and unlock shareholder value,' said Evangelos Perros, CFO of Pagaya. 'By replacing higher cost secured debt with long term unsecured capital, we are improving our operating leverage, cash generation, and strategic positioning in the marketplace.' About Pagaya Technologies Pagaya (NASDAQ: PGY) is a global technology company making life-changing financial products and services available to more people nationwide, as it reshapes the financial services ecosystem. By using machine learning, a vast data network and an AI-driven approach, Pagaya provides comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its proprietary API and capital solutions integrate into its network of partners to deliver seamless user experiences and greater access to the mainstream economy. Pagaya has offices in New York and Tel Aviv. Cautionary Note About Forward-Looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties. These forward-looking statements give our expectations or forecasts of future events and can generally be identified by the words 'anticipate,' 'believe,' 'continue,' 'can,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'opportunity,' 'future,' 'strategy,' 'might,' 'outlook,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. All statements other than statements of historical fact are forward-looking statements, including statements regarding the expected benefits of the notes offering. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering and the other risks and uncertainties described in the Company's filings with the SEC, included under the heading 'Risk Factors' in the Company's Annual Report on Form 10-K and any subsequent filings with the SEC. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These forward-looking statements reflect the Company's views with respect to future events as of the date hereof and are based on assumptions and subject to risks and uncertainties. The Company cannot provide any assurances regarding its ability to effectively apply the net proceeds of the offering or achieve the benefits described in this press release. Given these uncertainties, investors should not place undue reliance on these forward-looking statements. The forward-looking statements are made as of the date hereof, reflect the Company's current beliefs and are based on information currently available as of the date they are made, and the Company assumes no obligation and does not intend to update these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Globe and Mail
4 hours ago
- Globe and Mail
Valmont Board Declares Quarterly Dividend
Valmont® Industries, Inc. (NYSE: VMI), a global leader that provides products and solutions to support vital infrastructure and advance agricultural productivity, today announced that its Board of Directors has declared a quarterly dividend of $0.68 per share payable on October 15, 2025, to shareholders of record on September 26, 2025. The dividend indicates an annual rate of $2.72 per share. About Valmont Industries, Inc. For nearly 80 years, Valmont has been a global leader that provides products and solutions to support vital infrastructure and advance agricultural productivity. We are committed to customer-focused innovation that delivers lasting value. Learn more about how we're Conserving Resources. Improving Life. ® at
Globe and Mail
4 hours ago
- Globe and Mail
Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025. Mehta will lead Bio-Rad's global commercial strategy and execution, succeeding Mike Crowley, who is retiring after a distinguished 26-year career with the company. Mehta brings extensive leadership and commercial expertise in biopharmaceutical, life science research, and diagnostics markets to Bio-Rad. He joins from Labcorp, where he served as Senior Vice President, overseeing large-scale commercial operations for the company's West Division. Prior to Labcorp, Mehta was Vice President and General Manager, Applied Technologies, at Thermo Fisher Scientific. In this role, he successfully managed a global business unit serving diverse markets. Earlier in his career, Mehta held commercial roles of increasing responsibility at Dow Chemical, where he designed and executed impactful commercial growth strategies. He holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Electrical Engineering from Kurkshetra University in Thanesar, India. "Rajat's proven track record in delivering above-market growth, building high-achieving teams, and driving alignment across multiple business segments will be instrumental as we continue to advance our long-term strategy,' said Jon DiVincenzo, Bio-Rad's President and Chief Operating Officer. 'His focus on commercial excellence and deep understanding of large, global organizations spanning both clinical diagnostics and life science markets make him a fantastic addition to our leadership team." Norman Schwartz, Bio-Rad's Chairman and CEO, added, "On behalf of everyone at Bio-Rad, I want to extend our deepest gratitude and acknowledgement to Mike Crowley for his exceptional service and unwavering dedication. Since joining our commercial team in 1998, and particularly during his tenure as EVP of Global Commercial Operations since 2014, Mike's leadership has been instrumental in building our global sales and services organization and contributing to Bio-Rad's overall success.' About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,500 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit Forward-Looking Statements This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our executive officers. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations; global economic and geopolitical conditions; tariffs or other trade barriers; reductions in government funding or capital spending of our customers; the uncertain pace of the biopharma sector's recovery; international legal and regulatory risks; our ability to develop and market new or improved products; our ability to compete effectively; foreign currency exchange fluctuations; supply chain issues; product quality and liability issues; our ability to integrate acquired companies, products or technologies into our company successfully; changes in the healthcare industry; and natural disasters and other catastrophic events beyond our control. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
